NCI's Advanced Technology Partnerships Initiative
Mission
To accelerate the delivery of new products to cancer patients using a novel business/research model, advanced technologies, and effective public/private partnerships. Establish opportunities for collocation of synergistic biomedical research institutions and life science companies. Enable access to world-class technologies, capabilities, and scientific expertise in Cancer & HIV translational R&D through strategic partnerships.
Overview
- Initiated in 2007 as part of a National Cancer Institute strategic imperative
- Partnerships accomplished through FFRDC in Frederick, Maryland- a government-owned, contractor-operated national laboratory
- Includes in-reach activity to NCI programs and outreach activity to industry and academia
Benefits
- Designed to reduce time and cost associated with the translation of candidate drug products into effective interventions
- Utilize technology platforms to help partners allocate finite resources to high-probability candidates and move more rapidly through development and clinical testing
- Enables studies that partners my otherwise be unable to accomplish
- Access to diverse and integrated portfolio of cost-effective, state-of-the-art advanced technology platforms and to translational and clinical drug development expertise, distinct from drug discovery paradigm
- Expanded access to cGMP development and manufacturing capabilities and regulatory affairs support
Contractual Agreements |
Core Research Strengths |
- Flexible business mechanisms and contractual agreements such as:
- Material Transfer Agreements (MTA)
- Collaboration Agreements
- Testing Agreements
(platform technology development)
- Cooperative Research & Development Agreements (CRADA)
- Clinical Trial CRADAs (CT-CRADA)
- Clinical Trial Agreements (CTA)
- Small Business Innovative Research (SBIR) and
- Small Business Technology Transfer (STTR) Support
- Guest Researcher Agreements
- Technology transfer and commercialization opportunities
|
- Biopharmaceutical Development
- Moving early drug candidates from concept to clinic
- Proteins and Proteomics
- Expertise in macromolecular interactions
- Innovative solutions for access to proteins
- Proteomics discoveries through enabling technologies
- Specialty services in viral-based applications
- Imaging and Nanotechnology
- New applications in cancer therapeutics and diagnostics
- Cellular and molecular imaging expertise
- Integrated In Vivo Services
- Advanced translational research
- Advanced Biomedical Computing
- High-performance bioinformatics and modeling support
- Genetics and Genomics
- Systematic R&D in a high-throughput environment
|
Source: www.atpihome.com
|
